Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/115080
Title: | In vitro studies into establishing therapeutic bioequivalence of complex topical products: Weight of evidence | Authors: | Miranda, Margarida Volmer, Zoe Cornick, Alicia Goody, Aidan Cardoso, Catarina Pais, Alberto Brown, Marc Vitorino, Carla |
Keywords: | Topical bioequivalence; Antifungals; IVPT; Disease model; Regulatory science | Issue Date: | 10-May-2024 | Publisher: | Elsevier | Project: | PD/BDE/135075/ 2017 UID/ QUI/00313/2020 |
Serial title, monograph or event: | International Journal of Pharmaceutics | Volume: | 656 | Abstract: | Over the past decade, topically applied drug products have experienced extraordinary price increases, due to the shortage of multisource generic drug products. This occurrence is mainly related to the underlying challenges evolved in topical bioequivalence documentation. Although there has been continuing regulatory efforts to present surrogate in vitro methods to clinical endpoint studies, there is still a continued need for cost- and time-efficient alternatives that account for product specificities. Hence, this work intended to expose bioequivalence assessment issues for complex topical formulations, and more specifically those related with product efficacy guidance. As a model drug and product, a bifonazole 10 mg/g cream formulation was selected and two different batches of the commercially available Reference Product (RP) were used: RP1 that displayed lower viscosity and RP4 which presented high, but not the highest, viscosity. In vitro human skin permeation testing (IVPT) was carried out and the results were evaluated by means of the traditional bioequivalence assessment approach proposed by the EMA, as well as by the Scaled Average Bioequivalence assessment approach proposed by the FDA. Based on previous experience, there was an expectation of a high level of variability in the results, thus alternative methods to evaluate local drug skin availability were developed. More specifically, an infected skin disease model, where ex vivo human skin was infected and ATP levels were used as a biological marker for monitoring antifungal activity after product application. The results showed that permeation equivalence could not be supported between the different RP batches. In contrast, this statistical difference between the formulation batches was not indicated in the disease model. Nevertheless, in pivotal IVPT studies, the lowest permeant formulation (RP4) evidenced a higher antifungal in vitro activity as reported by the lower levels of ATP. A critical appraisal of the results is likewise presented, focusing on an outlook of the real applicability of the regulatory guidances on this subject. | URI: | https://hdl.handle.net/10316/115080 | ISSN: | 03785173 | DOI: | 10.1016/j.ijpharm.2024.124012 | Rights: | openAccess |
Appears in Collections: | FCTUC Química - Artigos em Revistas Internacionais I&D CQC - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
In vitro studies into establishing therapeutic bioequivalence of complex topical products Weight of evidence.pdf | 2.62 MB | Adobe PDF | View/Open |
Page view(s)
40
checked on Aug 14, 2024
Download(s)
17
checked on Aug 14, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License